Haleon is expected to report Q1 2026 revenue of approximately $3.80 billion and an EPS of $0.25, with the current stock price of $9.56 trading well below the average analyst price target of $12.33. Investors are primarily focused on the company's organic revenue growth, specifically looking for a recovery in the North American market after softness in late 2025.
Management has guided for full-year organic growth between 3% and 5%, which remains slightly below their medium-term target range of 4% to 6%. Markets are also monitoring the performance of 'Power Brands' like Sensodyne and Advil as Haleon implements its new operating model to drive agility and margin expansion.